Core Viewpoint - The company has announced the achievement of conditions for the second phase of its restricted stock incentive plan, allowing 106 eligible participants to claim a total of 799,271 shares at an adjusted price of 13.48 yuan per share, which represents 0.7768% of the company's total share capital [10][40]. Financial Data - The company confirmed that the third-quarter financial report was not audited [7]. - The financial report includes no adjustments or restatements of previous years' accounting data [3]. - The company reported no non-recurring gains or losses applicable [3]. Shareholder Information - The total number of shareholders holding more than 5% of shares and the top ten shareholders' holdings were not applicable for this report [5]. - The company has not experienced any changes in the lending of shares by major shareholders due to margin trading [5]. Incentive Plan Details - The second phase of the restricted stock incentive plan involves 106 eligible participants and a total of 799,271 shares [9][10]. - The adjusted grant price for the second phase is set at 13.48 yuan per share [11]. - The source of the shares for this incentive plan is from the company's repurchase of A-share common stock from the secondary market [12]. Approval Process - The board of directors approved the achievement of the second phase conditions on October 29, 2025, with unanimous support [36]. - The incentive plan has undergone necessary approvals and has been publicly disclosed as required [47][50]. Performance Conditions - The performance assessment for the incentive plan is based on company-level metrics for the fiscal years 2023-2025, with specific targets set for each year [22]. - Individual performance assessments will also be conducted according to the company's existing compensation and evaluation regulations [22]. Impact on Financial Status - The company anticipates that the stock grants will not significantly impact its financial status or operational results, as the total share capital will remain unchanged [49]. - The company will adjust the accounting treatment of the stock grants according to the applicable accounting standards [49].
恩威医药股份有限公司 2025年第三季度报告